TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $4.83 billion. The enterprise value is $4.87 billion.
Important Dates
The last earnings date was Monday, May 5, 2025, before market open.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 145.82 million shares outstanding. The number of shares has increased by 9.66% in one year.
| Current Share Class | 145.82M |
| Shares Outstanding | 145.82M |
| Shares Change (YoY) | +9.66% |
| Shares Change (QoQ) | +1.58% |
| Owned by Insiders (%) | 7.29% |
| Owned by Institutions (%) | 71.60% |
| Float | 135.13M |
Valuation Ratios
The trailing PE ratio is 139.00 and the forward PE ratio is 28.24. TG Therapeutics's PEG ratio is 0.25.
| PE Ratio | 139.00 |
| Forward PE | 28.24 |
| PS Ratio | 12.56 |
| Forward PS | 10.14 |
| PB Ratio | 20.42 |
| P/TBV Ratio | 20.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.25 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 124.33 |
| EV / Sales | 12.60 |
| EV / EBITDA | 81.30 |
| EV / EBIT | 81.37 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.07.
| Current Ratio | 4.02 |
| Quick Ratio | 2.91 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | 4.10 |
| Debt / FCF | n/a |
| Interest Coverage | 2.10 |
Financial Efficiency
Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 9.79%.
| Return on Equity (ROE) | 19.70% |
| Return on Assets (ROA) | 7.26% |
| Return on Invested Capital (ROIC) | 9.79% |
| Return on Capital Employed (ROCE) | 12.05% |
| Revenue Per Employee | $1.14M |
| Profits Per Employee | $115,828 |
| Employee Count | 338 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 0.41 |
Taxes
In the past 12 months, TG Therapeutics has paid $2.59 million in taxes.
| Income Tax | 2.59M |
| Effective Tax Rate | 6.21% |
Stock Price Statistics
The stock price has increased by +92.38% in the last 52 weeks. The beta is 2.21, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.21 |
| 52-Week Price Change | +92.38% |
| 50-Day Moving Average | 38.74 |
| 200-Day Moving Average | 30.25 |
| Relative Strength Index (RSI) | 36.69 |
| Average Volume (20 Days) | 3,167,430 |
Short Selling Information
The latest short interest is 23.11 million, so 15.85% of the outstanding shares have been sold short.
| Short Interest | 23.11M |
| Short Previous Month | 23.54M |
| Short % of Shares Out | 15.85% |
| Short % of Float | 17.11% |
| Short Ratio (days to cover) | 8.05 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $386.39 million and earned $39.15 million in profits. Earnings per share was $0.24.
| Revenue | 386.39M |
| Gross Profit | 337.80M |
| Operating Income | 59.82M |
| Pretax Income | n/a |
| Net Income | 39.15M |
| EBITDA | 59.87M |
| EBIT | 59.82M |
| Earnings Per Share (EPS) | $0.24 |
Full Income StatementBalance Sheet
The company has $276.24 million in cash and $254.58 million in debt, giving a net cash position of $21.66 million or $0.15 per share.
| Cash & Cash Equivalents | 276.24M |
| Total Debt | 254.58M |
| Net Cash | 21.66M |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 237.29M |
| Book Value Per Share | 1.63 |
| Working Capital | 484.30M |
Full Balance SheetCash Flow
| Operating Cash Flow | -61.03M |
| Capital Expenditures | -70,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 87.43%, with operating and profit margins of 15.48% and 10.13%.
| Gross Margin | 87.43% |
| Operating Margin | 15.48% |
| Pretax Margin | 10.80% |
| Profit Margin | 10.13% |
| EBITDA Margin | 15.49% |
| EBIT Margin | 15.48% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.66% |
| Shareholder Yield | -9.66% |
| Earnings Yield | 0.80% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for TG Therapeutics is $40.80, which is 23.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.80 |
| Price Target Difference | 23.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 36.90% |
| EPS Growth Forecast (5Y) | 100.29% |
Stock ForecastsStock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 0.0177777:1.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.0177777:1 |
Scores
TG Therapeutics has an Altman Z-Score of 3.66 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.66 |
| Piotroski F-Score | 3 |